Latest Research And Development News

Prescient Therapeutics has secured FDA clearance to initiate its Phase 2 PTX-100 trial for relapsed cutaneous T-cell lymphoma, alongside progress in its cell therapy platforms and a solid cash position bolstered by a recent R&D rebate.

Zimi Limited has secured $2.495 million through a capital raising, appointed new board members, and initiated cost-saving measures exceeding $400,000 annually, while navigating a compliance issue affecting sales to a major distributor.

Genetic Signatures reported a robust 190% increase in quarterly sales to $3.8 million, driven by strong respiratory testing demand in Australia and strategic UK deployments. Despite longer US sales cycles, the company maintains a solid $40.8 million cash position and advances R&D on its 3base® platform.

Connexion Mobility Limited reported a robust 15% revenue increase and a 43% jump in profit after tax for the half-year ended December 2024, underscoring its growing foothold in automotive SaaS solutions while continuing to invest in future growth.

INOVIQ's December quarterly update reveals significant progress in its cancer diagnostic and therapeutic programs, including a highly accurate ovarian cancer screening test and promising breast cancer therapeutics, supported by growing EXO-NET customer adoption and a solid cash position.

BluGlass Limited has secured over A$4 million in new contracts and filed three US patents for high-power tunable GaN lasers, reinforcing its leadership in visible laser technology and expanding its footprint in strategic photonics markets.

Pure Hydrogen advances its zero-emission vehicle strategy with key deliveries, US partnerships, and a planned demerger of its natural gas assets into Eastern Gas Limited.

Lumos Diagnostics reported a robust Q2 FY25 with a 71% revenue increase to US$2.9 million, driven by strong product and service sales, alongside a strategic US$3 million BARDA partnership to advance its FebriDx test.

Nanollose Limited has secured $2.1 million in strategic funding to accelerate the commercialisation of its sustainable fibres and soilless growth technologies, marking a pivotal shift from R&D to market-ready products.

One Click Group Limited reported a 42% increase in registered users and a 26% rise in revenue to $4.9 million in Q4 2024, while preparing to launch its new superannuation product in 2025.

Race Oncology has advanced its Phase 1 clinical trial for RC220, submitting ethics approvals and bolstering its cash reserves to $18.78 million following a $5.25 million R&D tax incentive.

Fluence Corporation Limited reported a net cash outflow of US$3.03 million for the December 2024 quarter, maintaining liquidity with nearly US$9 million in cash and expanded credit facilities.